Funder: National Institutes of Health
Due Dates: May 17, 2025 (Letter of Intent) | June 16, 2025 (New Applications) | July 16, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year.
Summary: Supports R21 research projects investigating actionable synthetic vulnerabilities paired with tumor responses to radiation therapy to develop new anticancer treatments.
Key Information: Clinical trials are optional; foreign and domestic applicants are eligible; updated March 2025—review full FOA for changes.